|
Santen Incorporated, a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd., opened its doors in the San Francisco Bay Area in 1993. Located in Northern California’s Napa Valley, the U.S. office is comprised of established, highly experienced healthcare professionals, led by President and CEO, Adrienne Graves, PhD. On average, each member of the U.S. senior management team has 20 or more years of industry experience, with extensive knowledge and expertise based exclusively in the ophthalmic field.
The leading ophthalmic pharmaceutical company in Japan since 1890, Santen specializes in treatments for eye and rheumatic diseases, offering both prescription and over-the-counter (OTC) products.
In early 2004, Santen entered into a partnership agreement with VISTAKON® Pharmaceuticals, LLC, granting VISTAKON the exclusive U.S. distribution rights to the established Santen ophthalmic products QUIXIN® (levofloxacin ophthalmic solution) 0.5%, BETIMOL® (timolol ophthalmic solution) 0.25% and 0.5%, and ALAMAST® (pemirolast potassium ophthalmic solution) 0.1%. This synergistic arrangement will enable Santen to move forward with a renewed emphasis on the discovery and development of exciting new products that will make a significant difference in eye care.
Santen's newest product IQUIX® (levofloxacin ophthalmic solution) 1.5%, gained FDA approval in March 2004. Santen is also actively pursuing technological alliances with a number of pharmaceutical companies and research institutes, and has investments in an intraocular lens company.
|
|
Back to top
|
|
|
